Patents Assigned to Cell Pathways, Inc.
  • Patent number: 6610854
    Abstract: Substituted condensation products of N-benzyl-3-indenylacetamides with heterocyclic aldehydes are useful for inducing or promoting apotosis and for arresting uncontrolled neoplastic cell proliferation, and are specifically useful in the arresting and treatment of neoplasias, including precancerous and cancerous lesions.
    Type: Grant
    Filed: July 26, 2002
    Date of Patent: August 26, 2003
    Assignees: Cell Pathways, Inc., University of Arizona
    Inventors: Gerhard J. Sperl, Paul Gross, Klaus Brendel, Gary A. Piazza, Rifat Pamukcu
  • Patent number: 6569638
    Abstract: This invention provides a method to identify compounds potentially useful for the treatment and prevention of neoplasia in mammals. The phosphodiesterase inhibitory activity of a compound is determined along with its ability to elevate JNK kinase activity. Growth inhibitory and apoptosis inducing effects on cultured tumor cells are also determined. Compounds that exhibit phosphodiesterase inhibition, an ability to elevate JNK kinase activity, growth inhibition and apoptosis induction are desirable for the treatment of neoplasia.
    Type: Grant
    Filed: March 3, 2000
    Date of Patent: May 27, 2003
    Assignee: Cell Pathways, Inc
    Inventors: I. Bernard Weinstein, W. Joseph Thompson, Jae-Won Soh, Li Liu, Han Li
  • Patent number: 6562830
    Abstract: Derivatives of 2-phenyl quinazolinones are useful for the treatment of patients having precancerous lesions. These compounds are also useful to inhibit growth of neoplastic cells.
    Type: Grant
    Filed: November 9, 1999
    Date of Patent: May 13, 2003
    Assignee: Cell Pathways, Inc.
    Inventors: Rifat Pamukcu, Gary A. Piazza
  • Patent number: 6555547
    Abstract: This invention provides a method for treating a patient with neoplasia by an adjuvant therapy that includes treatment with an antineoplastic vinca alkaloid derivative.
    Type: Grant
    Filed: February 28, 2000
    Date of Patent: April 29, 2003
    Assignee: Cell Pathways, Inc.
    Inventors: Rifat Pamukcu, Joseph M. Lobacki
  • Patent number: 6500610
    Abstract: This invention provides pharmaceutical compositions containing compounds for the treatment of neoplasia in mammals. The phosphodiesterase inhibitory activity of a compound is determined along with COX inhibitory activity. Growth inhibitory and apoptosis inducing effects on cultured tumor cells are also determined. Compounds that exhibit phosphodiesterase inhibiton, growth inhibition and apoptosis induction, but prefereably not substantial prostaglandin inhibitory activity, are desirable for the treatment of neoplasia.
    Type: Grant
    Filed: October 8, 1999
    Date of Patent: December 31, 2002
    Assignee: Cell Pathways, INC
    Inventors: Rifat Pamukcu, Gary A. Piazza
  • Patent number: 6486158
    Abstract: [4,5]-Fused-3,6 disubstituted-pydidazines of Formula I are useful for inducing or promoting apoptosis and for arresting uncontrolled neoplastic cell proliferation, and are specifically useful in the arresting and treatment of neoplasia: wherein Y1 and Y2 are independently selected from the group consisting of (CH2)n,—C(X)—NH—,—(CH2)n—C(X)—O—, and X is O or S; R1 is selected from the group consisting of lower alkyl, lower alkenyl, lower alkynyl, and substituted or unsubstituted phenyl, pyridinyl, and the like; R2 is selected from the group consisting of substituted or unsubstituted phenyl, benzyl, pyridinyl, and the like; “A” is a benzene ring fused with the pyridazine ring; and R3 is independently selected in each instance form the group consisting of halogen, lower alkyl, and the like.
    Type: Grant
    Filed: June 6, 2001
    Date of Patent: November 26, 2002
    Assignee: Cell Pathways, Inc.
    Inventors: Xiaojing Wang, Gerhard Sperl, Paul Gross, Rifat Pamukcu, Gary A. Piazza
  • Patent number: 6486155
    Abstract: A method for inhibiting neoplasia, particularly cancerous and precancerous lesions by exposing the affected cells to isoquinoline derivatives.
    Type: Grant
    Filed: November 24, 1998
    Date of Patent: November 26, 2002
    Assignee: Cell Pathways Inc
    Inventors: Rifat Pamukcu, Gary A. Piazza
  • Patent number: 6479520
    Abstract: Derivatives of phenyl pyridinone are useful for the treatment of patients having precancerous lesions. These compounds are also useful to inhibit the growth of neoplastic cells.
    Type: Grant
    Filed: March 8, 2000
    Date of Patent: November 12, 2002
    Assignee: Cell Pathways, Inc.
    Inventors: Gary Piazza, Rifat Pamukcu
  • Patent number: 6479493
    Abstract: Substituted condensation products of -benzyl-3-indenylacetamides with heterocyclic aldehydes and other such inhibitors are useful for the treatment of type I diabetes.
    Type: Grant
    Filed: August 23, 2001
    Date of Patent: November 12, 2002
    Assignee: Cell Pathways, Inc.
    Inventors: Clark M. Whitehead, Keith A. Earle, Hector W. Alila, W. Joseph Thompson
  • Patent number: 6472420
    Abstract: This invention provides a method for treating a patient with neoplasia by an adjuvant therapy that includes treatment with a paclitaxel derivative.
    Type: Grant
    Filed: January 3, 2002
    Date of Patent: October 29, 2002
    Assignee: Cell Pathways, Inc.
    Inventors: Rifat Pamukcu, Kerstin B. Menander
  • Patent number: 6465494
    Abstract: Substituted condensation products of N-benzyl-3-indenylacetamides with heterocyclic aldehydes and other such inhibitors are useful for the treatment of cystic fibrosis.
    Type: Grant
    Filed: August 24, 2001
    Date of Patent: October 15, 2002
    Assignee: Cell Pathways, Inc.
    Inventors: Keith A. Earle, Hector W. Alila, Clark M. Whitehead, W. Joseph Thompson
  • Patent number: 6455703
    Abstract: 1,3,6-Trihydro-6-Aza-3-Oxapentalen-2-One Derivatives which have the following formula: wherein R1, R2, R3, R4, R5, Y, X, m, and n are as defined in the specification.
    Type: Grant
    Filed: December 6, 2000
    Date of Patent: September 24, 2002
    Assignee: Cell Pathways, Inc.
    Inventors: Gerhard Sperl, Rifat Pamukcu
  • Patent number: 6440981
    Abstract: A method for inhibiting the growth of neoplastic cells by exposure to 2,9-disubstituted purin-6-ones.
    Type: Grant
    Filed: July 30, 2001
    Date of Patent: August 27, 2002
    Assignee: Cell Pathways, Inc.
    Inventors: Rifat Pamukcu, Gary A. Piazza
  • Patent number: 6420410
    Abstract: A method for inhibiting neoplastic cells and related conditions by exposing them to N,N′-substituted benzimidazol-2-ones.
    Type: Grant
    Filed: August 16, 2000
    Date of Patent: July 16, 2002
    Assignee: Cell Pathways, Inc.
    Inventors: Gerhard Sperl, Ulrich Ixkes, Rifat Pamukcu, Gary A. Piazza
  • Patent number: 6410584
    Abstract: A method for inhibiting neoplastic cells and related conditions by exposing them to substituted indole derivatives.
    Type: Grant
    Filed: November 25, 1998
    Date of Patent: June 25, 2002
    Assignee: Cell Pathways, Inc.
    Inventors: Rifat Pamukcu, Gary A. Piazza
  • Patent number: 6403831
    Abstract: Substituted benzylidene indenyl formamides, acetamides and propionamides are useful in the treatment of precancerous lesions and neoplasms.
    Type: Grant
    Filed: February 25, 2000
    Date of Patent: June 11, 2002
    Assignee: Cell Pathways, Inc.
    Inventors: Gerhard Sperl, Paul Gross, Klaus Brendel, Rifat Pamukcu, Gary A. Piazza
  • Patent number: 6391885
    Abstract: Derivatives of Phenyl Cycloamino Pyrimidinone are useful for the treatment of patients having precancerous lesions. These compounds are also useful to inhibit growth of neoplastic cells.
    Type: Grant
    Filed: May 4, 2000
    Date of Patent: May 21, 2002
    Assignee: Cell Pathways, Inc.
    Inventors: Gary A. Piazza, Rifat Pamukcu
  • Patent number: 6380206
    Abstract: A method for inhibiting neoplasia, particularly cancerous and precancerous lesions by exposing the affected cells to 4,5-diaminopyrimidine derivatives.
    Type: Grant
    Filed: May 7, 2001
    Date of Patent: April 30, 2002
    Assignee: Cell Pathways, Inc.
    Inventors: Rifat Pamukcu, Gary Piazza
  • Patent number: 6369092
    Abstract: A method for inhibiting neoplastic cells and related conditions by exposing them to substituted benzimidalole derivatives.
    Type: Grant
    Filed: April 30, 2001
    Date of Patent: April 9, 2002
    Assignee: Cell Pathways, Inc.
    Inventors: Rifat Pamukcu, Gary A. Piazza
  • Patent number: 6365627
    Abstract: This invention provides a method for treating a patient with neoplasia by an adjuvant therapy that includes treatment with a paclitaxel derivative.
    Type: Grant
    Filed: February 6, 2001
    Date of Patent: April 2, 2002
    Assignee: Cell Pathways, Inc.
    Inventors: Rifat Pamukcu, Kerstin B. Menander